Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Continues Emphasis On Rare Diseases With Pact For "Bubble Boy" Gene Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

Recently launched GSK rare diseases unit will focus on four primary therapeutic areas.

You may also be interested in...



Pfizer Increases Commitment To Rare Diseases With New Research Unit

In-licensing and development of so-called "bio-betters" will play critical roles in Pfizer's move, announced June 14, into the rare diseases space. The Rare Diseases Research Unit, to be overseen by Jose Carlos Gutierrez-Ramos, senior VP, Biotherapeutics Research and Development, will be part of Pfizer's worldwide R&D unit devoted to discovering novel medicines for orphan diseases, those affecting fewer than 200,000 patients. Initially it will target hemophilia and muscular dystrophy, both caused by genetic mutations

GSK Bolsters Orphan Drug Discovery By Signing Antisense Deal With Isis

Under the deal, which has all the hallmarks of a GSK option-based alliance, Isis gets $35 million upfront, and will deliver five drugs through PoC.

GSK Argues Its Strategy Is Delivering As Still More Cuts Are Made, Including in R&D

CEO Witty suggests group has emerged from worst of patent storm with an upbeat forecast for 2010 and promises of further cost-cutting.

Related Content

Topics

UsernamePublicRestriction

Register

PS071318

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel